HRP20040195B1 - Cjepivo protiv bolesti zapadnoga nila - Google Patents

Cjepivo protiv bolesti zapadnoga nila

Info

Publication number
HRP20040195B1
HRP20040195B1 HRP20040195AA HRP20040195A HRP20040195B1 HR P20040195 B1 HRP20040195 B1 HR P20040195B1 HR P20040195A A HRP20040195A A HR P20040195AA HR P20040195 A HRP20040195 A HR P20040195A HR P20040195 B1 HRP20040195 B1 HR P20040195B1
Authority
HR
Croatia
Prior art keywords
west nile
vaccine
provides
vaccine composition
disease
Prior art date
Application number
HRP20040195AA
Other languages
English (en)
Croatian (hr)
Inventor
Hsien-Jue Chu
Original Assignee
Zoetis W Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis W Llc filed Critical Zoetis W Llc
Publication of HRP20040195A2 publication Critical patent/HRP20040195A2/hr
Publication of HRP20040195B1 publication Critical patent/HRP20040195B1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HRP20040195AA 2001-07-27 2002-07-23 Cjepivo protiv bolesti zapadnoga nila HRP20040195B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30833401P 2001-07-27 2001-07-27
PCT/US2002/023447 WO2003061555A2 (en) 2001-07-27 2002-07-23 West nile vaccine

Publications (2)

Publication Number Publication Date
HRP20040195A2 HRP20040195A2 (en) 2004-08-31
HRP20040195B1 true HRP20040195B1 (hr) 2014-07-18

Family

ID=27613166

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20040195AA HRP20040195B1 (hr) 2001-07-27 2002-07-23 Cjepivo protiv bolesti zapadnoga nila

Country Status (24)

Country Link
US (8) US7153513B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (3) EP2283858A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP4718778B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (2) KR20040028952A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN1273189C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2002365244B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2014C006I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0211492B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2452545C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY2014010I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1427444T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2435095T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR14C0016I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20040195B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (2) HU228690B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU92348I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ME (1) ME00491B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA04000680A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (3) NZ570270A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL212212B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1427444E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (1) RS53184B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2003061555A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200401596B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425437B2 (en) * 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
HU228690B1 (en) * 2001-07-27 2013-05-28 Wyeth Corp West nile vaccine
EP1664786B1 (en) * 2003-09-09 2014-11-12 Idexx Laboratories, Inc. Detection of west nile virus infection and vaccination
US7074555B2 (en) * 2004-04-28 2006-07-11 Idexx Laboratories, Inc. Detection of West Nile Virus
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
WO2006029300A2 (en) 2004-09-09 2006-03-16 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
AU2006232865A1 (en) * 2005-04-01 2006-10-12 Wyeth Use of WNV DNA vaccine in combination with a conventional vaccine to overcome immunogen interference
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
EP1879921B1 (en) 2005-05-12 2011-04-27 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
EP1724338A1 (en) * 2005-05-19 2006-11-22 Crucell Holland B.V. Methods for the production of a whole-inactivated West Nile Virus vaccine
WO2006122964A1 (en) * 2005-05-19 2006-11-23 Crucell Holland B.V. Methods for the production of a whole-inactivated west nile virus vaccine
RU2436591C2 (ru) * 2005-06-24 2011-12-20 Интервет Интернэшнл Б.В. Инактивированные химерные вакцины и связанные с ними способы применения
NO346351B1 (no) * 2005-10-19 2022-06-20 Intervet Int Bv Isolert hundedyr influensa Avirus, polynukleotid-ekspresjonskonstruksjon, isolert antistoff, isolert celle, reassortant virus og rekombinant virusvektor, samt sammensetning og hundeinfluensavaksine
WO2007047728A2 (en) * 2005-10-20 2007-04-26 Wyeth Compositions and methods for the treatment of canine influenza virus disease
AU2006338210A1 (en) * 2005-12-14 2007-08-23 The Board Of Regents Of The University Of Oklahoma RNA virus vaccines and methods
EP2395018B1 (en) * 2006-06-06 2016-01-27 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
RU2489164C9 (ru) * 2007-11-06 2014-01-20 ВАЙЕТ ЭлЭлСи АВИРУЛЕНТНАЯ АДЪЮВАНТНАЯ ЖИВАЯ ВАКЦИНА ПРОТИВ Mycoplasma hyopneumoniae
CA2725329C (en) 2008-05-23 2013-10-01 The Regents Of The University Of Michigan Nanoemulsion vaccines
EP2306812A4 (en) * 2008-07-30 2013-02-20 Univ Kentucky Res Found EQUINE DISEASE MODEL FOR NEUROLOGICAL AUROPTIC VIRUS DISEASE AND USED ASSAYS
WO2010025469A1 (en) * 2008-08-29 2010-03-04 Boehringer Ingelheim Vetmedica, Inc. West nile virus vaccine
BR112012008185A2 (pt) * 2009-10-07 2016-08-16 Wyeth Llc composições que compreendem adjuvante, macrolídeo e antígeno proteináceo, e métodos para uso dessas composições
MX385188B (es) 2011-03-14 2025-03-14 Boehringer Ingelheim Vetmedica Inc Vacuna de rinitis equina.
CN103045544B (zh) * 2011-10-17 2015-01-14 华中农业大学 预防西尼罗河病毒的重组假型杆状病毒Bac-G-prM/E及疫苗与应用
EP3542819B1 (en) * 2013-05-14 2021-08-18 Zoetis Services LLC Novel vaccine compositions comprising immunostimulatory oligonucleotides
HK1224177A1 (zh) * 2013-09-05 2017-08-18 硕腾服务有限责任公司 Hendra和nipah病毒g糖蛋白免疫原性組合物
WO2017210215A1 (en) 2016-05-31 2017-12-07 The Government Of The United States Of America As Represented By The Secretary Of The Army Zika virus vaccine and methods of production
PL70842Y1 (pl) * 2017-08-25 2019-06-28 Gondek Lukasz Kuznia Mocy Urządzenie do regeneracji filtrów cząstek stałych i katalizatorów samochodowych
CN113905759A (zh) 2019-02-27 2022-01-07 罗切斯特大学 用于预防和控制马的马流感病毒(eiv)的多价减毒活流感疫苗

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020071A1 (fr) * 1993-03-08 1994-09-15 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile metabolisable
WO1995030437A1 (en) * 1994-05-10 1995-11-16 American Home Products Corporation Improved modified live brsv vaccine
WO2002072036A2 (en) * 2001-03-12 2002-09-19 Yale University Compositions and methods comprising west nile virus polypeptides
WO2002081754A1 (en) * 2001-04-04 2002-10-17 The Governement Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
WO2002081621A2 (fr) * 2001-04-06 2002-10-17 Merial Vaccin contre le virus de la fievre du nil

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US308334A (en) 1884-11-18 Ladder
US6184024B1 (en) 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
US5741696A (en) * 1992-08-07 1998-04-21 Syntro Corporation Recombinant equine herpesviruses
WO1999063095A1 (en) 1998-06-04 1999-12-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nucleic acid vaccines for prevention of flavivirus infection
US6733994B2 (en) 2000-10-04 2004-05-11 The Trustees Of The University Of Pennsylvania Highly expressible genes
WO2002068637A2 (en) 2000-10-20 2002-09-06 Ribozyme Pharmaceuticals, Inc. Nucleic acid-based treatment of diseases or conditions related to west nile virus infection
WO2002083903A2 (en) 2001-02-28 2002-10-24 Brown University Research Foundation West nile virus epitopes and uses thereof
US20030104008A1 (en) * 2001-04-06 2003-06-05 Loosmore Sheena May Recombinant vaccine against west nile virus
HU228690B1 (en) * 2001-07-27 2013-05-28 Wyeth Corp West nile vaccine
WO2004016586A2 (en) 2002-08-16 2004-02-26 Board Of Regents The University Of Texas System Compositions and methods related to flavivirus envelope protein domain iii antigens

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020071A1 (fr) * 1993-03-08 1994-09-15 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile metabolisable
US6235282B1 (en) * 1993-03-08 2001-05-22 Rhone Merieux Vaccinal fluid water-in-oil emulsions containing a metabolizable oil
WO1995030437A1 (en) * 1994-05-10 1995-11-16 American Home Products Corporation Improved modified live brsv vaccine
WO2002072036A2 (en) * 2001-03-12 2002-09-19 Yale University Compositions and methods comprising west nile virus polypeptides
WO2002081754A1 (en) * 2001-04-04 2002-10-17 The Governement Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
WO2002081621A2 (fr) * 2001-04-06 2002-10-17 Merial Vaccin contre le virus de la fievre du nil

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ALLISON A C: "SQUALENE AND SQUALANE EMULSIONS AS ADJUVANTS" METHODS : A COMPANION TO METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC., NEW YORK, NY, US, vol. 19, 1999, pages 87-93, XP001015570 ISSN: 1046-2023 *
ANDERSON J.F. ET AL.: 'Isolation of West Nile virus from Mosquitoes, Crows and a Cooper's Hawk in Connecticut' SCIENCE vol. 286, December 1999, pages 2331 - 2333, XP002191030 *
ARROYO J ET AL: "Yellow fever vector live-virus vaccines: West Nile virus vaccine development" TRENDS IN MOLECULAR MEDICINE, ELSEVIER CURRENT TRENDS, vol. 7, no. 8, August 2001 (2001-08), pages 350-354, XP002367847 ISSN: 1471-4914 *
DAVIS B S ET AL: "West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays" JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 75, no. 9, May 2001 (2001-05), pages 4040-4047, XP002239873 ISSN: 0022-538X *
LUSTIG S ET AL: "A LIVE ATTENUATED WEST NILE VIRUS STRAIN AS A POTENTIAL VETERINARY VACCINE" VIRAL IMMUNOLOGY, MARY ANN LIEBERT, INC., NEW YORK, US, vol. 13, no. 4, December 2000 (2000-12), pages 401-410, XP008018324 ISSN: 0882-8245 *
MONATH T P ET AL: "West Nile virus vaccine" CURRENT DRUG TARGETS, BENTHAM SCIENCE PUBLISHER,, US, vol. 1, no. 1, May 2001 (2001-05), pages 37-50, XP002967300 ISSN: 1389-4501 *
SENNE D.A. ET AL.: 'Pathogenicity of West Nile virus in Chickens' AVIAN DISEASES vol. 44, 2000, pages 642 - 649, XP002969115 *

Also Published As

Publication number Publication date
JP2011057692A (ja) 2011-03-24
JP4718778B2 (ja) 2011-07-06
BRPI0211492B1 (pt) 2016-06-21
US20070231349A1 (en) 2007-10-04
ES2435095T3 (es) 2013-12-18
HUP0401606A3 (en) 2005-02-28
HU228690B1 (en) 2013-05-28
CN1935258A (zh) 2007-03-28
WO2003061555A2 (en) 2003-07-31
CA2452545A1 (en) 2003-07-31
US20070166325A1 (en) 2007-07-19
HUP0401606A2 (hu) 2004-11-29
US20070178119A1 (en) 2007-08-02
JP2005515236A (ja) 2005-05-26
PL368535A1 (en) 2005-04-04
BE2014C006I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2021-02-04
US7445787B2 (en) 2008-11-04
LU92348I2 (fr) 2014-09-22
PL212212B1 (pl) 2012-08-31
KR20040028952A (ko) 2004-04-03
EP2281572A1 (en) 2011-02-09
CY2014010I1 (el) 2020-05-29
KR20090053967A (ko) 2009-05-28
HUS1300055I1 (hu) 2016-08-29
NZ531265A (en) 2008-08-29
AU2002365244B2 (en) 2007-12-06
FR14C0016I2 (fr) 2015-07-24
US20070231350A1 (en) 2007-10-04
US7153513B2 (en) 2006-12-26
US7648705B2 (en) 2010-01-19
US20070166324A1 (en) 2007-07-19
CY2014010I2 (el) 2024-02-16
CN1273189C (zh) 2006-09-06
PL398575A1 (pl) 2012-06-18
BR0211492A (pt) 2004-08-17
EP2283858A3 (en) 2011-03-23
CN1935258B (zh) 2013-04-03
DK1427444T3 (da) 2013-11-04
EP1427444A2 (en) 2004-06-16
EP1427444B1 (en) 2013-08-21
HK1066470A1 (en) 2005-03-24
CA2452545C (en) 2015-06-09
EP2283858A2 (en) 2011-02-16
NZ553165A (en) 2008-09-26
HRP20040195A2 (en) 2004-08-31
EP1427444A4 (en) 2008-01-02
LU92348I9 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2019-01-02
ME00491B (me) 2011-10-10
FR14C0016I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2014-03-28
NZ570270A (en) 2010-08-27
US7648706B2 (en) 2010-01-19
MXPA04000680A (es) 2004-04-05
YU8004A (sh) 2006-08-17
RS53184B (en) 2014-06-30
US20070166326A1 (en) 2007-07-19
PL220846B1 (pl) 2016-01-29
US20030091595A1 (en) 2003-05-15
CN1535157A (zh) 2004-10-06
WO2003061555A3 (en) 2004-04-15
US20070166802A1 (en) 2007-07-19
PT1427444E (pt) 2013-11-19
ZA200401596B (en) 2005-07-27

Similar Documents

Publication Publication Date Title
HRP20040195B1 (hr) Cjepivo protiv bolesti zapadnoga nila
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
UY27466A1 (es) Métodos y composiciones para el tratamiento de hepatitis c virus con 4'-modificaciones nucleosides
EA200201263A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
DE60024112D1 (de) Influenzavirus-impfstoffzusammensetzung
CO5050303A1 (es) Composicion farmaceutica para tratar infecciones virales y metodos para su preparacion su aplicacion
WO2007124479A3 (en) Avian influenza viruses, vaccines, compositions, formulations, and methods
ES2176232T3 (es) Vacuna adecuada para ser utilizada en la prevencion y tratamiento de la infeccion por helicobacter.
PE20070221A1 (es) Inhibidores macrociclicos del virus de la hepatitis c
BRPI9701774B8 (pt) cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
MX2022006742A (es) Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter.
EP1471936A4 (en) HIV VACCINE AND METHOD OF USE
IL182440A0 (en) Subtype-matched inactivated whole virus vaccines for treating patients with hiv infection
MXPA03009763A (es) Vacuna contra el virus de la enfermedad de la fiebre aftosa.
TW200617166A (en) Multivalent avian influenza vaccines
UA95299C2 (ru) Профилактический или терапевтический агент против вирусного заболевания, вызванного вирусом гепатита с
ATE330969T1 (de) Impfstoffe basierend auf mutanten des virus der infektiösen bursal-krankheit
ES2055610T3 (es) Vacuna contra hrsv.
CY1114624T1 (el) Εμβολιο δυτικου νειλου
DK1237571T3 (da) Toscana-virus-nukleinprotein

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: WYETH LLC, US

Owner name: ZOETIS W LLC, US

PPPP Transfer of rights

Owner name: PAH W LLC, US

B1PR Patent granted
PNAN Change of the applicant name, address/residence

Owner name: ZOETIS SERVICES LLC, US

PNAN Change of the applicant name, address/residence

Owner name: ZOETIS SERVICES LLC, US

ODRP Renewal fee for the maintenance of a patent

Payment date: 20190711

Year of fee payment: 18

ODRP Renewal fee for the maintenance of a patent

Payment date: 20200722

Year of fee payment: 19

ODRP Renewal fee for the maintenance of a patent

Payment date: 20210713

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20220723